...
首页> 外文期刊>Respiration: International Review of Thoracic Diseases >Serial pentamidine levels in bronchial epithelial lining fluid after aerosol administration.
【24h】

Serial pentamidine levels in bronchial epithelial lining fluid after aerosol administration.

机译:气雾剂给药后支气管上皮内衬液中的喷他idine水平连续升高。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: There is no information on serial pharmacokinetic assessment in the lungs after administration of aerosolized pentamidine. OBJECTIVE: The present study was performed to evaluate the elimination of aerosolized pentamidine from bronchial airways following inhalation. METHODS: We used 4 sheep with tracheotomies in the present study. Pentamidine (300 mg) was administered by inhalation to each animal. Serial bronchial washing to obtain epithelial lining fluid (ELF) was performed 1, 7, 10, 14, 21 and 28 days after administration of aerosolized pentamidine in each animal. The pentamidine concentration in the supernatant of ELF was measured by high-performance liquid chromatography. RESULTS: The maximal pentamidine level on the first day (12 h after inhalation) was 616.5 +/- 238.2 ng/ml (mean +/- SE) in ELF. The pentamidine levels rapidly decreased within 2 weeks (8.9 +/- 1.2 ng/ml at 14 days), followed by slow elimination (8.9 +/- 0.8 ng/ml at 28 days). Thus, inhaled pentamidine showed a rapid clearance from the bronchial wall within the first 2 weeks. CONCLUSIONS: These findings may be useful in designing and interpreting future studies of aerosolized pentamidine in patients who are receiving inhaled pentamidine, especially for those with failure of prophylaxis for Pneumocystis carinii pneumonia.
机译:背景:目前尚无关于雾化喷他idine后肺部系列药代动力学评估的信息。目的:本研究旨在评估吸入后从支气管气道中雾化的喷他idine的消除情况。方法:在本研究中,我们使用了4例进行气管切开术的绵羊。通过对每只动物吸入喷他idine(300 mg)。在每只动物中施用雾化喷他idine后1、7、10、14、21和28天,进行连续的支气管清洗以获得上皮内衬液(ELF)。通过高效液相色谱法测定ELF上清液中的喷他idine浓度。结果:ELF中第一天(吸入后12小时)的最大喷他idine水平为616.5 +/- 238.2 ng / ml(平均+/- SE)。喷他idine水平在2周内迅速下降(在14天时为8.9 +/- 1.2 ng / ml),然后缓慢消除(在28天时为8.9 +/- 0.8 ng / ml)。因此,吸入的喷他idine在头2周内显示从支气管壁快速清除。结论:这些发现可能在设计和解释雾化喷他idine在接受吸入喷他idine的患者,特别是那些预防卡氏肺孢子虫肺炎失败的患者中的未来研究中很有用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号